ScholarLens Back to search
1996•Europe PMC (PubMed Central)Requires access

Pharmacokinetics of monoclonal antibody HAb 18 and its F(ab^)_(2) and fab fragments in mice

Jiyun Yu, Yan-Fang Sui, Zhi‐Nan Chen, Mi Li, Fengchang He, Shuhang Wu, Bian Huijie, Chenggang Liu, Jinglan Deng

Open publisher page 3 citations

Abstract

The pharmacokinetics of 131I-labelled HAb18 McAb against primary hepatocellular carcinoma (PHC) and its F(ab^2) and Fab fragments following i.v. administration in BALB/c mice was investigated. Dynamic observations showed that the pharmacokinetics of 131I-labelled HAb18 was significantly different from that of the fragments. (1) The pharmacokinetics of HAb 18 conformed to a onecompart-mental open pharmacokinetic model. The clearance rate was relevant to injection doses, and the higher doses produced lower clearance values. (2) The pharmacokinetics of the F(ab^)_(2) was similar to that of the Fab and fitted to a two-compartmental pharmacokinetic model. The clearance process of the fragments was significantly fast than intact HAb18 McAb.

About this research paper

What this paper is about

The pharmacokinetics of 131I-labelled HAb18 McAb against primary hepatocellular carcinoma (PHC) and its F(ab^2) and Fab fragments following i.v. administration in BALB/c mice was investigated. Dynamic observations showed that the pharmacokinetics of 131I-labelled HAb18 was significantly different from that of the fragments. (1) The pharmacokinetics of HAb 18 conformed to a onecompart-mental open pharmacokinetic model. The clearance rate was relevant to injection doses, and the higher doses produced lower clearance values. (2) The pharmacokinetics of the F(ab^)_(2) was similar to that of the Fab and fitted to a two-compartmental pharmacokinetic model. The clearance process of the fragments was significantly fast than intact HAb18 McAb.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The pharmacokinetics of 131I-labelled HAb18 McAb against primary hepatocellular carcinoma (PHC) and its F(ab^2) and Fab fragments following i.v. administration in BALB/c mice was investigated. Dynamic observations showed that the pharmacokinetics of 131I-labelled HAb18 was significantly different from that of the fragments. (1) The pharmacokinetics of HAb 18 conformed to a onecompart-mental open pharmacokinetic model. The clearance rate was relevant to injection doses, and the higher doses produced lower clearance values. (2) The pharmacokinetics of the F(ab^)_(2) was similar to that of the Fab and fitted to a two-compartmental pharmacokinetic model. The clearance process of the fragments was significantly fast than intact HAb18 McAb.

Key concepts: Pharmacokinetics, Monoclonal antibody, Chemistry, Pharmacology, Clearance rate, Plasma clearance, Clearance, Hepatocellular carcinoma

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Pharmacokinetics of monoclonal antibody HAb 18 and its F(ab^)_(2) and fab fragments in mice — Research Paper | ScholarLens